Antibodies to the acetylcholine receptor and HLA antigens have been studied in patients with myasthenia gravis occurring in association with penicillamine treatment. The properties of the antiacetylcholine receptor in these patients differed from those in patients with idiopathic myasthenia gravis in terms of specificity and affinity. These patients had an increased prevalence of HLA Bw35 and DRi compared to controls and a decreased frequency of B8 and DR3 compared to patients with idiopathic myasthenia gravis. Likewise, they had a decreased frequency of DR4 compared to patients with rheumatoid arthritis.
Discussion
Scleroderma of the lung' and the proximal muscles2 has been well described but not, to our knowledge, scleroderma of the diaphragm. Diaphragmatic symptoms have been described in systemic lupus erythematosus,3 but the clinical picture and low level of anti-DNA antibody and the findings at necropsy militate against a diagnosis of this or of mixed connective tissue disease. The raised activity of creatinine phosphokinase in this patient suggest that the myopathy may have fitted into the pattern of inflammatory myopathy,4 which might, therefore, have responded to treatment with corticosteroids. We suggest that the extensive fibrosis with accompanying degeneration of the myofibrils within skeletal type muscle in the diaphragm (figure) was secondary to scleroderma and a contributing factor to the terminal respiratory failure. Diaphragmatic changes should, therefore, be added to the list of respiratory complications in scleroderma.
Introduction
For many years penicillamine has been used in the treatment of rheumatoid arthritis. The drug has been implicated in the induction of several autoimmune diseases, including myasthenia gravis.' The myasthenia gravis induced by penicillamine is clinically indistinguishable from idiopathic myasthenia gravis and is invariably associated with the presence of antibodies to the acetylcholine receptor. After withdrawal of penicillamine, titres of antiacetylcholine receptor usually fall and myasthenia gravis resolves. ' The aetiological agent in idiopathic myasthenia gravis is unknown. In Caucasians the HLA antigens B8 and DR3 are known to be increased, particularly in those patients with early onset of disease and thymic hyperplasia. 2 We have previously reported that antiacetylcholine receptor in patients with penicillamine induced myasthenia gravis is less cross reactive than that from patients with idiopathic myasthenia gravis.5 Antiacetylcholine receptor in penicillamine induced myasthenia gravis tends to have a higher average affinity (see below). These data suggest that penicillamine induced myasthenia gravis is subtly different from the idiopathic disease and support the conclusion that penicillamine may induce myasthenia gravis.
The identification of genetic factors that predispose to the induction of myasthenia gravis by penicillamine would provide further such evidence. More importantly, the identification of a susceptible genetic background, combined with the knowledge of the aetiological agent, would provide a unique opportunity to study the pathogenesis of myasthenia gravis.
In a preliminary report we noted that Caucasian patients with penicillamine induced myasthenia gravis have a higher than expected prevalence of Bw35 and DR1. 6 We now present the full typing data and compare prevalences of HLA types in these patients with those in patients with rheumatoid arthritis, patients with idiopathic myasthenia gravis, and controls.
Patients and methods
Clinical details and sera were supplied by several clinicians throughout Australia, New Zealand, United Kingdom, and the United States of America. All but two patients were being treated for rheumatoid arthritis. One of the exceptions was receiving penicillamine for scleroderma7 and the other for Wilson's disease.8 All were Caucasian.
Tissue typing was performed using standard microlymphocytotoxicity techniques.9 Typing was done in the patients' own area and the HLA types supplied by their clinicians. Details on 12 patients were collected by this laboratory. These have been combined with details of four cases whose HLA data and antiacetylcholine receptor titre have been published by others.7 10-12 All 16 patients were typed for HLA-A and HLA-B antigens and 10 of these were also typed for DR.
Since the patients were derived from several centres throughout the world an appropriate control group was difficult to obtain. Antigen prevalences have been compared with those found in healthy Cauca- Results ANTIACETYLCHOLINE RECEPTOR Figure 2 shows titres of antiacetylcholine receptor in patients with penicillamine induced myasthenia gravis. All four patients who had titres < 1 unit were in remission at the time of assay. Table I shows the average binding affinities and titres of antiacetylcholine receptor in patients with idiopathic (n = 14) and penicillamine induced (n = 11) myasthenia gravis. Patients with penicillamine induced disease had higher affinities (p = 0 025; MannWhitney U test). analysis, but using sera at high dilution and having effectively removed IgG from their preparations of acetylcholine receptor, have reported average affinities of antiacetylcholine receptor in idiopathic myasthenia gravis similar to those reported here. Our data show that antiacetylcholine receptor in patients with penicillamine induced myasthenia gravis was generally of higher average affinity than that from patients with idiopathic disease. The HLA antigens Bw35 and DRI were associated with penicillamine induced myasthenia gravis. The increased prevalence of DRI in patients with penicillamine induced disease has recently been confirmed.'7 The relative absence of DR4 from the patients with penicillamine induced disease also suggests that these patients are genetically distinct from the remaining patients with rheumatoid arthritis. DRI has, however, been shown to be increased in patients with rheumatoid arthritis in two different racial groups"8 19 while Bw35 and DR1 may be associated with DR4-negative rheumatoid arthritis in Caucasians (P Kay et al, unpublished observations).
HLA TYPES
The relative scarcity of B8 and DR3 in patients with penicillamine induced myasthenia gravis (see also reference 17) contrasts with its increased prevalence in patients with idiopathic myasthenia gravis, particularly in women with early onset. Interestingly Bw35 and DRI do influence susceptibility to myasthenia gravis especially in Asian Indians.20 Thus one interpretation of our data would be that DR3 and DR4 favour myasthenia gravis and rheumatoid arthritis respectively, whereas the combination of Bw35 and DRI permits both. Alternatively Bw35 and DR1 may allow a specific reaction with penicillamine or may be a marker for genetic factors affecting immunoregulation." Some interesting parallels exist. Insulin dependent diabetes mellitus has been shown to be associated with more than one HLA supratype." Hydralazine induced systemic lupus erythematosus is associated with DR4 although the idiopathic disease is not.23
The temporal relationship between administration or withdrawal of penicillamine and onset or remission of disease, the subtle differences in properties of antiacetylcholine receptor, and the distinct HLA association all indicate that penicillamine may induce myasthenia gravis. The demonstration of the association with HLA-Bw35 and DR1 should allow progress in investigation of the mechanisms of induction of antiacetylcholine receptor and myasthenia gravis.
